MLKL and neoplasm: Although CT26 tumor cells do not express RIPK318, the therapeutic effect of MLKL-mRNA treatment resulted in a very pronounced antitumor effect, increasing the median survival time to >60 days and 60% of the treated mice even remained tumor free up to 80 days after CT26 inoculation (Fig. 2c and Supplementary Fig. 3).